Benefits
Cholesterol and Triglyceride Reduction
Mollace 2011, Toth 2016, and others show BPF reduces LDL cholesterol (~24-36%), triglycerides (~30-39%), and total cholesterol while raising HDL. Effect comparable to low-dose statins for some markers. Multiple confirmatory RCTs.
Glycemic Improvement
Trials show BPF reduces fasting blood glucose, HbA1c, and improves insulin sensitivity in metabolic syndrome and prediabetic populations. Mechanism: AMPK activation, gluconeogenesis modulation.
Statin Adjunct (Reduces Statin Doses)
Gliozzi 2013 trial showed BPF + low-dose rosuvastatin (10 mg) was equivalent or superior to higher-dose rosuvastatin (20 mg) alone — suggesting BPF allows lower statin dosing with potentially fewer side effects. Important practical cardiovascular application.
NAFLD / Hepatic Steatosis
BPF reduces liver enzymes (ALT, AST, GGT) and hepatic steatosis markers in NAFLD patients. Mechanism: AMPK activation, reduced de novo lipogenesis.
Distinct from Bergamot Essential Oil
Important consumer education: bergamot ESSENTIAL OIL (used in Earl Grey tea flavoring, perfumes) is the photosensitizing aromatic oil from peel — DIFFERENT from the polyphenolic fraction (BPF) used in supplements. Don't confuse the products.
Mechanism of action
HMG-CoA Reductase Inhibition (Statin-Like Flavanones)
Brutieridin and melitidin have structural similarity to statins and inhibit HMG-CoA reductase — same target as statins and red yeast rice. May explain cholesterol-lowering effects.
AMPK Activation
BPF activates AMP-activated protein kinase (AMPK) — master metabolic regulator. AMPK activation reduces lipogenesis, increases fat oxidation, improves insulin sensitivity. Similar mechanism to metformin and exercise.
Antioxidant Activity
BPF flavonoids (neoeriocitrin, naringin, neohesperidin) are potent antioxidants — protect LDL particles from oxidation, reduce inflammatory markers. Cardiovascular protective beyond just lipid lowering.
Gut Microbiome Effects
Emerging research: BPF polyphenols modulate gut microbiome composition, increase short-chain fatty acid producers — additional metabolic benefit pathway.
Clinical trials
RCT of BPF (500 or 1,000 mg/day) vs placebo in 237 patients with hyperlipidemia for 30 days.
237 hyperlipidemia patients.
BPF significantly reduced LDL (24% at 500 mg, 36% at 1,000 mg), total cholesterol, triglycerides; raised HDL. Foundational trial establishing BPF as effective cholesterol agent. Effect dose-dependent.
RCT comparing rosuvastatin 10 mg + BPF 1,000 mg vs rosuvastatin 10 mg vs rosuvastatin 20 mg in mixed dyslipidemia patients for 30 days.
77 mixed dyslipidemia patients.
Rosuvastatin + BPF combination produced LDL reduction comparable to or better than higher-dose rosuvastatin alone. Important practical implication: BPF allows lower statin dosing with potentially fewer side effects.
About this ingredient
Citrus bergamot (Citrus bergamia) is a SOUR ORANGE variety from CALABRIA, Italy — used historically for Earl Grey tea flavoring (essential oil) and now for cardiovascular/metabolic supplementation (polyphenolic fraction).
CRITICAL DISTINCTION: BERGAMOT ESSENTIAL OIL (peel oil) contains photosensitizing FUROCOUMARINS (bergapten) — used in flavoring, perfumes, NOT for oral cardiovascular supplementation; vs BERGAMOT POLYPHENOLIC FRACTION (BPF) — standardized water/ethanol extract from juice, fruit pulp; furocoumarin-FREE; used in cardiovascular supplements. KEY ACTIVE COMPOUNDS in BPF: BRUTIERIDIN and MELITIDIN (statin-like flavanones; structurally similar to statins; HMG-CoA reductase inhibitors), NEOERIOCITRIN, NARINGIN, NEOHESPERIDIN (antioxidant flavonoids). BRANDED FORMS: BERGAMONTE® (HP Ingredients) — most clinically-studied; BERGAMET® (Bergamet Brands); both standardized to ~38% polyphenols.
EVIDENCE-BASED USES: (1) HYPERLIPIDEMIA — Mollace 2011 (24-36% LDL reduction); strong dose-response evidence; (2) METABOLIC SYNDROME / TYPE 2 DIABETES — glycemic improvement; (3) STATIN ADJUNCT — Gliozzi 2013 — allows LOWER statin doses with comparable LDL reduction; clinically valuable; (4) NAFLD adjunct — modest evidence; (5) GENERAL CARDIOVASCULAR SUPPORT.
CRITICAL CAUTIONS: (1) BERGAMOT ESSENTIAL OIL IS DIFFERENT — photosensitizing; furocoumarins; NOT for oral cardiovascular supplementation; verify product is BPF (polyphenolic fraction); (2) STATIN COMBINATION — BPF + low-dose statin is genuinely useful clinically; consult cardiologist before adjusting prescription doses; (3) DIABETES MEDICATIONS — modest hypoglycemic effect; monitor blood glucose with insulin/sulfonylureas; (4) ANTIHYPERTENSIVES — modest BP reduction; monitor; (5) PREGNANCY/LACTATION — limited safety data at supplemental doses; AVOID; (6) STANDARDIZATION — verify product is standardized BPF (e.g., Bergamonte® or Bergamet®) with furocoumarin removal; cheap unstandardized 'bergamot' products may contain bergamot essential oil contaminants; (7) DOSE — 500-1,500 mg/day BPF; 1,000 mg often optimal; (8) For ESTABLISHED CVD or HIGH-RISK, prescription statins remain gold standard with established outcome evidence; BPF is reasonable adjunct or alternative for milder cases; (9) The Mollace trials demonstrate BPF is one of the more clinically-validated supplements for cholesterol — comparable to many low-dose statin trials; this distinguishes it from many supplement claims with weaker evidence.